Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter RSV (Palivizumab Biosimilar) Antikörper

Reaktivität: Human FACS, in vivo Wirt: Maus Monoclonal unconjugated Recombinant Antibody
Produktnummer ABIN7200664
  • Target Alle RSV (Palivizumab Biosimilar) Produkte
    RSV (Palivizumab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human
    Wirt
    • 1
    Maus
    Klonalität
    • 1
    Monoklonal
    Konjugat
    • 1
    Dieser RSV (Palivizumab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Verwendungszweck
    Palivizumab Biosimilar, RSV Monoclonal Antibody
    Spezifität
    The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
    Produktmerkmale
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Aufreinigung
    Protein A affinity column
    Reinheit
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterilität
    0.2 μm filtered
    Endotoxin-Niveau
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Konservierungsmittel
    Without preservative
    Handhabung
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Haltbarkeit
    12 months
  • Target
    RSV (Palivizumab Biosimilar)
    Abstract
    RSV (Palivizumab Biosimilar) Produkte
    Substanzklasse
    Biosimilar
    Hintergrund
    Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Sie sind hier:
Kundenservice